FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRACEMARK OFFICE

ATTY, DOCKET NO. ORYXE,001A

APPLICATION NO. 09/350,043

#4

INFORMATION DISCLOSURE STATEMENT

BY APPLICANT

APPLICANT

Frederick L. Jordan

RECEIVED

(USE SEVERAL SHEETS IF NECESSARY)

FILING DATE July 8, 1999

**U.S. PATENT DOCUMENTS** 

SROUPION 2 3 1999

**CHNOLOGY CENTER 3700** 

	Š	<i>y</i>			! · · ·			
ENT &	ER L		DOCUMENT NUMBER **	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
4	5	1.	5,318,960	6-7-94	TOPPO	514	159	6-3-92
		2.	5,571,671	11-5-96	POTTER	435	6	3-23-94
		3.	5,614,212	3-25-97	D'ANGELO ET AL.	424	449	10-19-93
		4.	5,665,378	9-9-97	DAVIS ET AL.	424	448	11-21-95
		5.	5,708,038	1-13-98	DAVIS	514	783	6-13-96
		6.	5,744,368	4-28-98	GOLDGABER, ET AL.	436	501	11-4-93
		7.	5,837,853	11-17-98	TAKASHIMA, ET AL.	536	24.5	2-20-96
		8.	5,840,746	11-24-98	DUCHARME ET AL.	514	438	9-5-97
		9.	5,861,268	1-19-99	TANG ET AL.	435	25	5-23-96
		10.	5,885,597	3-23-99	BOTKNECHT ET AL.	424	401	10-1-97
$ egin{array}{c} \end{array} $	/	11.	5,891,651	4-6-99	ROCHE ET AL.	435	21	3-29-96
41	3	12.	5,891,857	4-6-99	HOLT ET AL.	514	44	2-20-96
						1		

FOREIGN PATENT DOCUMENTS								
EXAMINER	DOCUMENT NUMBER DA	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
INITIAL						YES	NO	
13.	98/34629	8-13-98	PS WO	6		х	_	
	<u> </u>							

EXAMINER INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

S:\DOCS\ESF\ESF-1778.DOC 102099

EXAMINER

BAWA

DATE CONSIDERED

2/10/01

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

•				•	<u> </u>	<u> </u>			S	SHEET 2 OF	
FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. ORYXE.001A		APPLIC. 09/350	ATION NO. ),043					
	INFC	RMATION DISCLOSURE	STATEMENT								
BY APPLICANT					APPLICANT Frederick L. Jordan				<i></i>		
USE SEVERAL SHEETS IF NECESSARY)				FILING DATE July 8, 1999		GRODA 3 61	EQFJ)	<b>IED</b>	<u> </u>		
2 2 199	9	5				er e an	N	10V 23	1999		
101 5				U	J.S. PATENT DOCUMENTS CHNOLOGY CENTER 3700				)		
INITIAL		DOCUMENT NUMBE	R DATE		NAME		CLASS	SUBCLASS		DATE OPRIATE)	
			ļ								
			*	FOR	REIGN PATENT DOCUMENTS						
EXAMINER	Π	DOCUMENT NUMBE	R DATE		COUNTRY		CLASS	SUBCLASS	TRANSLATION		
INITIAL							Ì		YES	NO	
EXAMINER INITIAL			OTHER DOCUME	ENTS (	INCLUDING AUTHOR, TITLE, DATE,	PERTINENT	PAGES, I	ETC.)			
213	Downing et al., Dermatology in General Medicine, Fitzpatrick, et al., eds., pp. 210-221 (199									•	
11	15.	Ponec, M., Epidermal lipids in vivo, The Keratinocyte Handbook, Leigh, et al., eds., pp. 351-363 (1994))									
					August: 26-33 (1993)						
	17.	Amadio et al., Nonsteroidal anti-inflammatory drugs, Postgraduate Medicine, 93(4):73-97 (1993)									
	18.	http://www.natplus.com/products/ productNumber = 7124-									
	19.	http://www.botanical.com/botanical/mgmh/f/franki31.html									
	20.	Cohen, et al. in Wound Healing/Biochemical and Clinical Aspects, 1st ed. WB Saunders, Philadelphia (1992)									
	21.	Grindlay and Reynolds, The Aloe Vera Phenomenon: A Review of the Properties and Modern Uses of the Leaf Parenchyma Gel, (1986) J. of Ethnopharmacology 16:117-151									
	22.		nctionally and	Chem	ically Distinct Immunomodul	atory Com	npounds	in the Gel	of Aloe V	Vera,	
	23.										

S:\DOCS\ESF\ESF-1780.DOC 102199

EXAMINER	BAWA	DATE CONSIDERED 2	10	0(
			-	

Comparison between Two Commercial Instruments, Skin Pharmacol. 8:186-195 (1995)

Bronaugh and Maibach, Boca Raton, Fl, CRC Press, pp237-241 (1991)

The Society for Investigative Dermatology, Inc.. 874-879 (1991)

Toxicology and Applied Pharmacology, 99:522-533 (1989)

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Bronaugh and Collier, In vitro Percutaneous absorption studies: Principle, Fundementals, and Applications, eds.

Barel and Clarys, Study of the Stratum corneum Barrier Function by Transepidermal Water Loss Measurements:

Collier et al., Maintenance of Skin Viability during in Vitro Percuteneous Absorption/Metabolism Studies,

Nelson et al., Mid-Infrared Laser Ablation of Stratum Corneum Enhances in Vitro Percutaneous Transport of Drugs,